NewAmsterdam Pharma Company N.V. (NAMS) Return on equity 2022–2025
NewAmsterdam Pharma Company N.V. (NAMS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-29.8%FY2025 · since FY2022: -5.3% → -29.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -29.8% | +2.1 pp |
| FY2024 | -31.9% | +29.5 pp |
| FY2023 | -61.4% | -56.1 pp |
| FY2022 | -5.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More NAMS financial trends
NAMS RevenueNAMS Net incomeNAMS Net marginNAMS Gross profitNAMS Gross marginNAMS Operating incomeNAMS Operating marginNAMS Operating cash flowNAMS Free cash flowNAMS Capital expendituresNAMS Stock buybacksNAMS Dividends paidNAMS Total assetsNAMS Total liabilitiesNAMS Shareholders’ equityNAMS overview →